留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

中国人群胰腺癌与胃癌HER2/neu基因表达

任新瑜 尹玉峰 高洁 武莎斐 王可 王文泽 曾瑄 梁智勇

任新瑜, 尹玉峰, 高洁, 武莎斐, 王可, 王文泽, 曾瑄, 梁智勇. 中国人群胰腺癌与胃癌HER2/neu基因表达[J]. 协和医学杂志, 2012, 3(1): 21-25. doi: 10.3969/j.issn.1674-9081.2012.01.006
引用本文: 任新瑜, 尹玉峰, 高洁, 武莎斐, 王可, 王文泽, 曾瑄, 梁智勇. 中国人群胰腺癌与胃癌HER2/neu基因表达[J]. 协和医学杂志, 2012, 3(1): 21-25. doi: 10.3969/j.issn.1674-9081.2012.01.006
Xin-yu REN, Yu-feng YIN, Jie GAO, Sha-fei WU, Ke WANG, Wen-ze WANG, Xuan ZENG, Zhi-yong LIANG. Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 21-25. doi: 10.3969/j.issn.1674-9081.2012.01.006
Citation: Xin-yu REN, Yu-feng YIN, Jie GAO, Sha-fei WU, Ke WANG, Wen-ze WANG, Xuan ZENG, Zhi-yong LIANG. Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(1): 21-25. doi: 10.3969/j.issn.1674-9081.2012.01.006

中国人群胰腺癌与胃癌HER2/neu基因表达

doi: 10.3969/j.issn.1674-9081.2012.01.006
详细信息
    通讯作者:

    梁智勇 电话:010-65295969, E-mail:liangzhiyong1220@yahoo.com

  • 中图分类号: R737.9

Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients

More Information
  • 摘要:   目的  探讨胰腺癌与胃癌组织中HER2/neu基因表达状态及其在治疗与评估临床结局中的作用。  方法  应用免疫组织化学和多色荧光原位杂交技术, 检测北京协和医院手术切除的81例胰腺导管癌及癌旁胰腺组织和100例胃癌及癌旁胃组织标本中HER2/neu蛋白表达及基因状态的变化, 分析HER2/neu蛋白表达与基因状态间的关系及其与胰腺癌和胃癌临床病理改变间的关系。  结果  免疫组织化学显示, 81例胰腺癌组织中9例(11.1%)HER2/neu蛋白表达阳性(2+及3+), 100例胃癌组织中13例(13%)HER2/neu蛋白表达阳性(2+及3+); 荧光原位杂交结果显示, 81例胰腺癌组织中15例(18.5%)HER2/neu基因扩增, 100例胃癌组织中11例(11%)HER2/neu基因扩增。胰腺癌HER2/neu基因扩增与淋巴结转移有显著相关性(P=0.001)。胃癌组织中6例HER2/neu蛋白3+病例均显示HER2/neu基因扩增, 且胃癌组织HER2/neu蛋白表达与其基因扩增有显著相关性(P < 0.0001)。无论是癌旁胰腺组织还是癌旁胃组织均未检测到HER2/neu蛋白表达及基因扩增。  结论  胰腺癌组织HER2/neu蛋白表达与基因扩增不一致, 而胃癌组织HER2/neu蛋白表达与基因扩增有显著相关性。HER2/neu基因异常可能在胰腺癌及胃癌的发生发展中起着重要作用, 对胰腺癌及胃癌患者进行HER2/neu基因状态检测可能对其靶向治疗具有一定的指导意义。
  • 图  1  胰腺导管腺癌组织中HER2/neu蛋白阳性表达(3 +)

    图  2  荧光原位杂交示胰腺导管腺癌HER2/neu基因扩增

    红色信号为HER2 /neu基因, 绿色信号为17号染色体着丝粒

    图  3  胃腺癌组织中HER2/neu蛋白阳性表达(3 +)

    图  4  荧光原位杂交示胃腺癌HER2/neu基因扩增

    红色信号为HER2 /neu基因, 绿色信号为17号染色体着丝粒

    表  1  胰腺癌组织HER2/neu蛋白表达和基因扩增的相关性

    表  2  胃癌组织HER2/neu蛋白表达与基因扩增的相关性

  • [1] Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2009, 59:225-249. doi:  10.3322/caac.20006
    [2] Pancreatric Section, British Society of Gastroenterology; Pancreatic Society of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; Royal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas[J]. Gut, 2005, 54 Suppl 5: v1-v16.
    [3] Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer[J]. New Eng J Med, 2006, 355:11-22. doi:  10.1056/NEJMoa055531
    [4] Hoffmann I, Eugene E, Nassif X, et al. Actination of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitides[J]. J Cell Biol, 2001, 155:133-143. doi:  10.1083/jcb.200106148
    [5] Scheurle D, Jahanzeb M, Aronsohn RS, et al. Her-2/neu expression in archival non-small cell carcinoma at heterogeneous levels by HLA-A2. 1-restricted cytotoxic T lymphocytes[J]. Int J Cancer, 2000, 87:349-359. doi:  10.1002/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O
    [6] Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244:707-712. doi:  10.1126/science.2470152
    [7] Kauraniemi P, Kallioniemi A. Activation of multiple cancer associated genes at the ERBB2 amplicon in breast cancer[J]. Endocr Relat Cancer, 2006, 13:39-49. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=06c06223567caa1931ad0d2e6a4093f4
    [8] Flaherty KT, Brose MS. Her-2 targeted therapy:beyond breast cancer and trastuzumab[J]. Curr Oncol Rep, 2006, 8:90-95. doi:  10.1007/s11912-006-0042-4
    [9] Hansel DE, Ashfaq R, Rahman A, et al. A subset of pancreatic adenocarcinomas demonstrates complication of topoisomerase Ⅱα and HER2/NEU:use of immunolabeling and multicolor FISH for potential patient screening and treatment[J]. Am J ClinPathol, 2005, 123:28-35. http://www.ncbi.nlm.nih.gov/pubmed/15762277
    [10] Coussens L, Yang-Feng TL, Liao YC, te al. Tyrosine kinase receptor with extensive homology to EGFR receptor shares chromosomal location with neu oncogene[J]. Science, 1985, 230:1132-1139. doi:  10.1126/science.2999974
    [11] Cho HS, Leahy DJ. Stucture of the extracellular region of HER3 reveals an interdomain tether[J]. Science, 2002, 297:1330-1333. doi:  10.1126/science.1074611
    [12] Garrett TP, Mckern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha[J]. Cell, 2002, 110:763-773. doi:  10.1016/S0092-8674(02)00940-6
    [13] Gravalos1 C, Jimeno A. HER2 in gastric cancer:a new prognostic factor and a novel therapeutic target[J]. Ann Oncol, 2008, 19:1523-1529. doi:  10.1093/annonc/mdn169
    [14] Arya G, Vandana M, Acharya S, et al. Enhanced antiproliferative activity of Herceptin (HER2) -cojugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy[J]. Nanomedicine, 2011, 7:859-870. doi:  10.1016/j.nano.2011.03.009
    [15] Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma[J]. Br JCancer, 2011, 104:1372-1376. doi:  10.1038/bjc.2011.121
    [16] Day JD, Digiuseppe JA, Yeo C, et al. Immunohistochemical evaluation of HER2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms[J]. Hum Pathol, 1996, 27:119-124. doi:  10.1016/S0046-8177(96)90364-0
    [17] Dugan MC, Dergham ST, Kucway R, et al. HER2/neu expression in pancreatic adenocarcinoma:telation to tumor differentiation and survival[J]. Pancreas, 1997, 14:229-236. doi:  10.1097/00006676-199704000-00003
    [18] Langner C, Gross C, Rehak P, et al. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma:systematic analysis applying tissue microarray technique[J]. Urology, 2005, 65:176-180. doi:  10.1016/j.urology.2004.08.025
    [19] Nakamura H, Saji H, Ogata A, et al. Correlation between encoded protein over expression and copy number of the HER2 gene with survival in non-small cell lung cancer[J]. Int J Cancer, 2003, 103:61-66. doi:  10.1002/ijc.10795
    [20] Schlüter B, Gerhards R, Strumberg D, et al. Combined detection of Her2/neu gene amplification and protein over expression in effusions from patients with breast and ovarian cancer[J]. J Cancer Res Clin Oncol, 2010, 136:1389-1400. doi:  10.1007/s00432-010-0790-2
    [21] Apple SK, Hecht JR, Lewin DN, et al. Immunohistochemical evaluation of K-ras, P53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas:evidence for multistep carcinogenesis[J]. Hum Pathol, 1999, 30:123-129. doi:  10.1016/S0046-8177(99)90265-4
    [22] Mihaljevic A, Büchler P, Harder J, et al. A prospective, non-randomized phase Ⅱ trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer[J]. BMC Surg, 2009, 9:1. doi:  10.1186/1471-2482-9-1
    [23] Fornaro L, Lucchesi M, Caparello C, et al. Anti-HER agents in gastric cancer:from bench to bedside[J]. Nat Rev Gastroenterol Hepatol, 2011, 8:369-383. doi:  10.1038/nrgastro.2011.81
  • 加载中
图(4) / 表(2)
计量
  • 文章访问数:  433
  • HTML全文浏览量:  135
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-12-09
  • 刊出日期:  2012-10-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!